Topics

"Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non‐Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib" Drugs and Medication Database

21:36 EST 18th January 2020 | BioPortfolio

Here are the most relevant "Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non‐Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib" Drugs and Medications that we have found in our database.

More Information about "Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non‐Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib" on BioPortfolio

We have published hundreds of Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non‐Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib news stories on BioPortfolio along with dozens of Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non‐Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib Clinical Trials and PubMed Articles about Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non‐Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non‐Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib Companies in our database. You can also find out about relevant Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non‐Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib Drugs and Medications on this site too.

Showing "Atezolizumab Bevacizumab Epidermal Growth Factor Receptor EGFR Mutant" Drugs and Medications 1–25 of 93

Relevant

Mvasi [amgen inc]

These highlights do not include all the information needed to use MVASI safely and effectively. See full prescribing information for MVASI .     MVASI (bevacizumab-awwb ) Solution for intravenous infusion Initial U.S. Approval: 2017 MVASI (bevacizumab-

Probably Relevant

Erbitux [imclone llc]

These highlights do not include all the information needed to use ERBITUX safely and effectively. See full prescribing information for ERBITUX.ERBITUX (cetuximab) injection, for intravenous useInitial U.S. Approval: 2004

Tecentriq [genentech, inc.]

These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. TECENTRIQ (atezolizumab) injection, for intravenous useInitial U.S. Approval: 2016

Possibly Relevant

Folotyn [allos therapeutics]

These highlights do not include all the information needed to use FOLOTYN safely and effectively. See full prescribing information for FOLOTYN.FOLOTYN (pralatrexate injection), for intravenous use Initial U.S. Approval: 2009

Baxdela [melinta therapeutics, inc]

These highlights do not include all the information needed to use BAXDELA safely and effectively. See full prescribing information for BAXDELA. BAXDELA (delafloxacin) tablets, for oral use BAXDELA (delafloxacin) for injection, for intravenous use Initial

Entresto [novartis pharmaceuticals corporation]

These highlights do not include all the information needed to use ENTRESTO safely and effectively. See full prescribing information for ENTRESTO. ENTRESTO (sacubitril and valsartan) tablets, for oral use Initial U.S. Approval: 2015

Tagrisso [astrazeneca pharmaceuticals lp]

These highlights do not include all the information needed to use TAGRISSO safely and effectively. See full prescribing information for TAGRISSO. TAGRISSO (osimertinib) tablets, for oral useInitial U.S. Approval: 2015

Cyramza [eli lilly and company]

These highlights do not include all the information needed to use CYRAMZA safely and effectively. See full prescribing information for CYRAMZA.CYRAMZA (ramucirumab) injection, for intravenous useInitial U.S. Approval: 2014

Vectibix [amgen inc]

These highlights do not include all the information needed to use VECTIBIX safely and effectively. See full prescribing information for VECTIBIX .     VECTIBIX   (panitumumab)   I njection for intravenous use Initial U.S. Approval: 200 6

Gilotrif [boehringer ingelheim pharmaceuticals, inc.]

These highlights do not include all the information needed to use GILOTRIF safely and effectively. See full prescribing information for GILOTRIF. GILOTRIF (afatinib) tablets, for oral useInitial U.S. Approval: 2013

Vizimpro [u.s. pharmaceuticals]

These highlights do not include all the information needed to use VIZIMPRO safely and effectively. See full prescribing information for VIZIMPRO. VIZIMPRO (dacomitinib) tablets, for oral use Initial U.S. Approval: 2018

Vizimpro [pfizer laboratories div pfizer inc]

These highlights do not include all the information needed to use VIZIMPRO safely and effectively. See full prescribing information for VIZIMPRO. VIZIMPRO (dacomitinib) tablets, for oral use Initial U.S. Approval: 2018

Farxiga [a-s medication solutions]

These highlights do not include all the information needed to use FARXIGA safely and effectively. See full prescribing information for FARXIGA. FARXIGA (dapagliflozin) tablets, for oral useInitial U.S. Approval: 2014

Iressa [astrazeneca pharmaceuticals lp]

These highlights do not include all the information needed to use IRESSA safely and effectively. See full prescribing information for IRESSAIRESSA(gefitinib) tablets for oral useInitial U.S. Approval: 2015

Bosulif [u.s. pharmaceuticals]

These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. BOSULIF (bosutinib) tablets, for oral use Initial U.S. Approval: 2012

Farxiga [astrazeneca pharmaceuticals lp]

These highlights do not include all the information needed to use FARXIGA safely and effectively. See full prescribing information for FARXIGA. FARXIGA (dapagliflozin) tablets, for oral useInitial U.S. Approval: 2014

Farxiga [cardinal health]

These highlights do not include all the information needed to use FARXIGA safely and effectively. See full prescribing information for FARXIGA. FARXIGA (dapagliflozin) tablets, for oral useInitial U.S. Approval: 2014

Avastin [genentech, inc.]

These highlights do not include all the information needed to use AVASTIN safely and effectively. See full prescribing information for AVASTIN. AVASTIN (bevacizumab) injection, for intravenous useInitial U.S. Approval: 2004

Tarceva [genentech, inc.]

These highlights do not include all the information needed to use TARCEVA safely and effectively. See full prescribing information for TARCEVA.TARCEVA (erlotinib) tablets, for oral useInitial U.S. Approval: 2004

Repaglinide and metformin hydrochloride [lupin pharmaceuticals, inc.]

These highlights do not include all the information needed to use REPAGLINIDE AND METFORMIN HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for REPAGLINIDE AND METFORMIN HYDROCHLORIDE TABLETS. REPAGLINIDE and METFORMIN hydro

Metformin hydrochloride [legacy pharmaceutical packaging, llc]

These highlights do not include all the information needed to use METFORMIN HYDROCHLORIDE TABLETS  safely and effectively. See full prescribing information for METFORMIN HYDROCHLORIDE TABLETS . METFORMIN HYDROCHLORIDE tablets, for oral  use Initial U.S.

Adlyxin [sanofi-aventis u.s. llc]

These highlights do not include all the information needed to use ADLYXIN safely and effectively. See full prescribing information for ADLYXIN. ADLYXIN (lixisenatide) injection, for subcutaneous use Initial U.S. Approval: 2016

Demeclocycline hydrochloride [epic pharma, llc]

Demeclocycline Hydrochloride Tablets Rx Only

Demeclocycline hydrochloride [puracap laboratories llc]

Demeclocycline Hydrochloride Tablets Rx Only

Bosulif [pfizer laboratories div pfizer inc]

These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. BOSULIF(bosutinib) tablets, for oral use Initial U.S. Approval: 2012



Quick Search